呼吸内科病历抗感染药物的药物利用研究

目的 评估某综合医院呼吸科抗感染药物应用情况.方法 随机抽取呼吸科2006年2月份入院的100份病历,对抗感染药物应用情况进行统计分析,以药物利用指数(DUI)作为分析判断指标.结果 DUI为0.9～1.1占33.33%,疗程为6.6天,每日抗感染药费为296.3元,使用频度最高的是β-内酰胺类,13例患者发生抗感染药物不良反应.结论 该院呼吸科抗感染药物应用基本合理,但存在抗感染药物联合使用不当、药费过高、频繁更换抗感染药物等问题,应加强合理用药的监督和指导.     

中药与西药联合应用的分析

目的探讨中西药联合应用的优势、禁忌与注意事项,供临床工作者参考。方法参考中西药文献,对中西药联合应用的优势、禁忌与注意事项等方面进行分析。结果在临床用药过程中,掌握中西药联合应用的配伍禁忌和注意事项,减少甚至避免了药物的不良反应。结论要加强中西药相互作用的研究,在临床用药过程中,掌握好中西药联合应用的配伍禁忌,减少不良反应的发生率。     

Personalized Medicine: Four Perspectives of Tailored Medicine

With the rapid advancement of scientific understanding in the medical field, everyday use of personalized medicine appears within our grasp. Unfortunately, there are still challenges to overcome. In many therapeutic areas, there remains a lack of deep understanding of disease processes and treatments. Additionally, drug development proceeds over a 5–10 year timeframe, during which time knowledge of treatments and potential predictive biomarkers continues to evolve. For successful development of a drug that is tailored to a biomarker-defined patient population and approved by regulators for such use, employment of appropriate statistical design and analysis methods is paramount. Consequently, statisticians can play a leading role in transforming the practice of medicine to a more personalized approach. We describe four perspectives in clinical development, together with examples of each, and discuss how to approach the problem of demonstrating that a treatment works better in a biomarker-defined subgroup of patients than in its complementary subgroup. The four perspectives provide a framework for design of clinical trials and subsequent analyses as they relate to clinical development. Subgroup identification is described as a controlled, disciplined search for finding the right patient for treatment and is distinguished from traditional, exploratory subgroup analysis.     

浅谈中西药的相互作用

目的:对中西药的相互作用进行探讨,促进中西药合理联用。方法:检索近年来文献报道,进行整理汇总。结果与结论:只有在了解组方中各种药物化学成分的性质及药理作用的前提下,进行最佳的配伍,才能避免不良的药物相互作用,真正发挥中西药联合应用的价值,提高疗效。